Antares' testosterone injection found successful in late-stage study

(Reuters) - Antares Pharma Inc said its once-weekly testosterone injection met the main goal in an ongoing late-stage study in testosterone-deficient adult males. The U.S. Food and Drug Administration asked Antares last month for additional safety data on the drug, to be sold as QuickShot Testosterone, after a patient developed hives in a separate mid-stage trial. The current late-stage study is testing the drug, known chemically as testosterone enanthate, in 150 patients whose testosterone blood levels are less than 300 nanograms per deciliter. QuickShot Testosterone, or QST, is the only self-administered subcutaneous treatment in late-stage development, giving it an edge over existing injectables that must be administered directly into the muscle by a doctor. via Health News Headlines - Yahoo News Read More Here..